Andrew D. Fesnak

Andrew D. Fesnak

Auto-generated profile, based on publicly available information

Andrew D. Fesnak

Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2020 in Science
Verified
Journal Article
Closed access
PDF file
ESEdward A. Stadtmauer
Edward A. Stadtmauer
JFJoseph A. Fraietta
Joseph A. Fraietta
MDMegan M. Davis
Megan M. Davis
ACAdam Cohen
Adam Cohen
KWKristy L. Weber
Kristy L. Weber
CJCarl H. June
Carl H. June
CRISPR takes first steps in humans: CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They removed immune cells called T lymphocytes from patients and used CRISPR-Cas9 to disrupt three genes ( TRAC, TRBC , and PDCD1 ) with the goal of improving antitumor immunity. A cancer-targeting transgene, NY-ESO-1, was also introduced to recognize tumors. The engineered cells were administered to patients and were well tolerated, with durable engraftment observed for the study duration. These encouraging observations pave the way for future trials to study CRISPR-engineered cancer immunotherapies. Science , this issue p. eaba7365 ; see also p. 976

23 August 2016 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
AFAndrew D. Fesnak
Andrew D. Fesnak
CJCarl H. June
Carl H. June
BLBruce L. Levine
Bruce L. Levine

20 September 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RMRegina M. Myers
Regina M. Myers
YLYimei Li
Yimei Li
ALAllison Barz Leahy
Allison Barz Leahy
DBDavid M. Barrett
David M. Barrett
DTDavid Trent Teachey
David Trent Teachey
SMShannon L. Maude
Shannon L. Maude
PURPOSE: CD19-targeted chimeric antigen receptor (CAR)–modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed. METHODS: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblastic lymphoma (n = 2), treated in two cohorts: with (retreatment, n = 33) or without (CAR-naive, n = 41) prior CAR exposure. Patients were monitored for toxicity, response, and persistence of huCART19. RESULTS: Seventy-four patients 1-29 years of age received huCART19. Cytokine release syndrome developed in 62 (84%) patients and was grade 4 in five (6.8%). Neurologic toxicities were reported in 29 (39%), three (4%) grade 3 or 4, and fully resolved in all cases. The overall response rate at 1 month after infusion was 98% (100% in B-ALL) in the CAR-naive cohort and 64% in the retreatment cohort. At 6 months, the probability of losing huCART19 persistence was 27% (95% CI, 14 to 41) for CAR-naive and 48% (95% CI, 30 to 64) for retreatment patients, whereas the incidence of B-cell recovery was 15% (95% CI, 6 to 28) and 58% (95% CI, 33 to 77), respectively. Relapse-free survival at 12 and 24 months, respectively, was 84% (95% CI, 72 to 97) and 74% (95% CI, 60 to 90) in CAR-naive and 74% (95% CI, 56 to 97) and 58% (95% CI, 37 to 90) in retreatment cohorts. CONCLUSION: HuCART19 achieved durable remissions with long-term persistence in children and young adults with relapsed or refractory B-ALL, including after failure of prior CAR T-cell therapy.

15 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KBKatharine J. Bar
Katharine J. Bar
PSPamela A. Shaw
Pamela A. Shaw
GCGrace H. Choi
Grace H. Choi
NANicole Aqui
Nicole Aqui
AFAndrew Fesnak
Andrew Fesnak
PTPablo Tebas
Pablo Tebas
Background. Antibody-based strategies for COVID-19 have shown promise in prevention and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely used but results from randomized trials supporting its benefit in hospitalized patients with pneumonia are limited. Here, we assess the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia. Methods. We performed a randomized control trial (PennCCP2), with 80 adults hospitalized with COVID-19 pneumonia, comparing up to 2 units of locally sourced CCP plus standard care versus standard care alone. The primary efficacy endpoint was comparison of a clinical severity score. Key secondary outcomes include 14- and 28-day mortality, 14- and 28-day maximum 8-point WHO ordinal score (WHO8) score, duration of supplemental oxygenation or mechanical ventilation, respiratory SARS-CoV-2 RNA, and anti–SARS-CoV-2 antibodies. Results. Eighty hospitalized adults with confirmed COVID-19 pneumonia were enrolled at median day 6 of symptoms and day 1 of hospitalization; 60% were anti–SARS-CoV-2 antibody seronegative. Participants had a median of 3 comorbidities, including risk factors for severe COVID-19 and immunosuppression. CCP treatment was safe and conferred significant benefit by clinical severity score (median [MED] and interquartile range [IQR] 10 [5.5–30] vs. 7 [2.75–12.25], P = 0.037) and 28-day mortality (n = 10, 26% vs. n = 2, 5%; P = 0.013). All other prespecified outcome measures showed weak evidence toward benefit of CCP. Conclusion. Two units of locally sourced CCP administered early in hospitalization to majority seronegative participants conferred a significant benefit in clinical severity score and 28-day mortality. Results suggest CCP may benefit select populations, especially those with comorbidities who are treated early. Trial Registration. ClinicalTrials.gov NCT04397757. Funding. University of Pennsylvania.

1 July 2016 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
AFAndrew Fesnak
Andrew Fesnak
CLChieYu Lin
ChieYu Lin
DSDon L. Siegel
Don L. Siegel
MMMarcela V. Maus
Marcela V. Maus

4 June 2015 in Blood
Verified
Journal Article
Open access
PDF file
MKMobin A. Karimi
Mobin A. Karimi
JBJerrod L. Bryson
Jerrod L. Bryson
LRLee P. Richman
Lee P. Richman
AFAndrew D. Fesnak
Andrew D. Fesnak
TLTheresa M. Leichner
Theresa M. Leichner
TKTaku Kambayashi
Taku Kambayashi
In allogeneic hematopoietic stem cell transplantation (HSCT), controlling graft-versus-host disease (GVHD) while maintaining graft-versus-tumor (GVT) responses is of critical importance. Using a mouse model of allogeneic HSCT, we hereby demonstrate that NKG2D expression by CD8+ T cells plays a major role in mediating GVHD and GVT effects by promoting the survival and cytotoxic function of CD8+ T cells. The expression of NKG2D ligands was not induced persistently on normal tissues of allogeneic HSCT–recipient mice treated with anti-NKG2D antibody, suggesting that transient NKG2D blockade might be sufficient to attenuate GVHD and allow CD8+ T cells to regain their GVT function. Indeed, short-term treatment with anti-NKG2D antibody restored GVT effects while maintaining an attenuated GVHD state. NKG2D expression was also detected on CD8+ T cells from allogeneic HSCT patients and trended to be higher in those with active GVHD. Together, these data support a novel role for NKG2D expression by CD8+ T cells during allogeneic HSCT, which could be potentially therapeutically exploited to separate GVHD from GVT effects. Key Points NKG2D enhances cytotoxicity and survival of CD8+ T cells, which contributes to GVHD and GVT effects after allogeneic HSCT. The temporally distinct expression pattern of NKG2D ligands may allow separation of GVHD and GVT effects by transient NKG2D blockade.